The Strategic Goals, Organizational Health Goals, and Performance Goals in the CSP 2021 outline the opportunities to accelerate our progress towards our VISION and to achieve significant and sustainable growth.
①Strategic Goals
VALUE creation and delivery will be maximized by pursuing these 4 goals:
This reflects our commitment towards maximizing:
i. Sustainable patient access to our portfolio
ii. Outcomes that those patients achieve as a consequence
Taking our execution of the Focus Area approach to the next level by:
i. Accelerating proof of VALUE and expansion of our Primary Focuses
ii. Effective exploration of the cutting-edge of biopharmaceutical innovation
We continue to pursue this groundbreaking path to turn innovative science into VALUE for patients.
The Rx+® business will commercialize multiple solutions during this CSP period while building and accelerating its pipeline.
We recognize the importance of our commitment to sustainability; maximizing positive societal impact and being recognized for it.
②Organizational Health Goals
We have adopted three Organizational Health Goals (OHG) to foster an internal environment where exceptional execution and performance are cultivated and sustained over time:
People are empowered to take appropriate risks and supported to be ‘outcome-driven’ and ‘innovation-focused.’
Purposeful talent management with a consistent leadership style that enables the desired mindset and behaviors.
People co-operate effectively, with robust and coordinated execution, to achieve common goals.
③Performance Goals
Performance Goals enable us to measure successful execution of CSP2021 and indicate our aspirations in financial terms. We define our targets in three key aspects:
At least 1.2 trillion yen in sales of XTANDI and key strategic products* in fiscal year 2025
*XOSPATA, PADCEV, Evrenzo, Fezolinetant, Zolbetuximab, Resamirigene bilparvovec (AT132)
Expected sales from Focus Area assets of more than 500 billion yen in fiscal year 2030
More than 30% core operating profit margin in fiscal year 2025
By achieving these Performance Goals, we will improve our current benefit and also increase our pipeline value, a value that will bring robust growth in the future. To this end, we aim to become a company with a market capitalization valued at more than 7 trillion yen in fiscal year 2025.
Click here to read more about our Performance Goals.
Three Interconnected Goals Accelerate the Execution
Click here to overview of CSP 2021
Related Links
